Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)-Reference-Cited by-同舟云学术

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

Published:2010-05-12 Issue:9 Volume:49 Page:1683-1693
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Rubbert-Roth A.,Tak P. P.,Zerbini C.,Tremblay J.-L.,Carreno L.,Armstrong G.,Collinson N.,Shaw T. M.,

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/49/9/1683/5050686/keq116.pdf

Reference21 articles.

1. Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

2. Consensus statement on the use of rituximab in patients with rheumatoid arthritis

3. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

4. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

5. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis;Arthritis Research & Therapy;2024-06-06

2. DMARDS incorporated injectable hydrogels in cartilage tissue regeneration: a review;Polymer-Plastics Technology and Materials;2024-06-04

3. B-cell depletion in autoimmune diseases;Annals of the Rheumatic Diseases;2024-05-22

4. Non-TNF biologics and their biosimilars in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-05-22

5. Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?;BioDrugs;2023-10-13